Last reviewed · How we verify
10d TL quadruple therapy
At a glance
| Generic name | 10d TL quadruple therapy |
|---|---|
| Also known as | esomeprazole 40 mg, tripotassium dicitrate bismuthate 300mg, tetracycline 500 mg, levofloxacin 500 mg |
| Sponsor | Ping-I (William) Hsu, M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 10d TL quadruple therapy CI brief — competitive landscape report
- 10d TL quadruple therapy updates RSS · CI watch RSS
- Ping-I (William) Hsu, M.D. portfolio CI